{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-003153","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.016782+00:00","generated_at":"2026-05-16T10:58:27.365424+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Turn Therapeutics provides pipeline update; GX-03 Phase 2 data expected H1 2026, appoints Martin Dewhurst to board","bullets":["Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track; interim and topline data expected first half of 2026.","Martin Dewhurst (30+ year McKinsey M&A veteran) appointed to Board of Directors.","Vaccine pipeline expanded to include intranasal influenza candidate; in-vivo/vitro studies start Q1 2026.","Commercial partnership with Medline expected to generate near-term revenue in 2026 in wound care.","Strengthened balance sheet via share purchase agreement extends cash runway into late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-003153","json":"https://secwatch.observer/filing/0001213900-26-003153.json","markdown":"https://secwatch.observer/filing/0001213900-26-003153.md","text":"https://secwatch.observer/filing/0001213900-26-003153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026003153/0001213900-26-003153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026003153/ea0272490-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:58:27.365424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}